

Ligand-based pharmacophore modeling using novel 3D pharmacophore signatures

Alina Kutlushina ¹, Aigul Khakimova ¹, Timur Madzhidov ¹, Pavel Polishchuk ^{2,*}

¹ A.M. Butlerov Institute of Chemistry, Kazan Federal University, Kremlevskaya Str. 18, Kazan, Russia

² Institute of Molecular and Translational Medicine, Faculty of Medicine and Dentistry, Palacký University and University Hospital in Olomouc, Hnevotinska 5, 77900 Olomouc, Czech Republic

* Correspondence: pavlo.polishchuk@upol.cz; Tel.: +420 585632298

Supporting materials




Figure S1. Precision-recall plot of 3D ligand-based pharmacophore models built on AChE inhibitors.




Figure S2. Precision-recall plot of 3D ligand-based pharmacophore models built on adenosine 2a antagonists.




Figure S3. Precision-recall plot of 3D ligand-based pharmacophore models built on CYP450 3A4 inhibitors.




Figure S4. Performance of 3D ligand-based pharmacophore models built on AChE inhibitors and comparison with the best result of similarity search based on 2D pharmacophore fingerprints.




Figure S5. Performance of 3D ligand-based pharmacophore models built on adenosine 2a antagonists and comparison with the best result of similarity search based on 2D pharmacophore fingerprints.




Figure S6. Performance of 3D ligand-based pharmacophore models built on CYP450 3A4 inhibitors and comparison with the best result of similarity search based on 2D pharmacophore fingerprints.